Status:
UNKNOWN
Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Rectal Carcinoma
Sigmoid Colon Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This is a prospective randomized controlled study. investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group to compare the differences of lymph nodes disse...
Detailed Description
ICG is a registered and FDA-approved non-specific fluorescent probe for optical imaging in clinical settings. The properties of ICG ,which is a water-soluble amphiphilic molecule with a molecular weig...
Eligibility Criteria
Inclusion
- (1)18-80 years of age (2)American Society of Anesthesiologists (ASA) class 1-3 (3)single rectal or sigmoid colon carcinoma confirmed pathologically by endoscopic biopsy (4)planned laparoscopic radical resection (5)Written informed consent
Exclusion
- previous abdominal tumor surgery
- women who are pregnant or breast feeding
- emergency patients with obstruction or perforation
- T4b cancer evaluated by CT or MRI or endoscopic ultrasonography
- pelvic or distant metastasis
- T1 cancer planned local excision
- allergic constitution patients
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04848311
Start Date
May 1 2021
End Date
May 1 2022
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510000